Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: Hertax trial

Clinical Breast Cancer

Volumn 11, Issue 2, 2011, Pages 103-113

  Hamberg, Paul ^a   Bos, Monique M E M ^b   Braun, Hans J J ^c   Stouthard, Jacqueline M L ^d   Van Deijk, Gert A ^e   Erdkamp, Frans L G ^f   Van Der Stelt Frissen, Iris N ^a   Bontenbal, Marijke ^a   Creemers, Geert Jan M ^g   Portielje, Johanneke E A ^e   Pruijt, Johannes F M ^h   Loosveld, Olaf J L ⁱ   Smit, Willem M ^j   Muller, Erik W ^k   Schmitz, Paul I M ^a   Seynaeve, Caroline ^a   Klijn, Jan G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c Vlietland Hospital   (Netherlands)

^d Maasstad Hospital Rotterdam   (Netherlands)

^e HAGA HOSPITAL   (Netherlands)

^f Sittard Geleen Heerlen   (Netherlands)

^g CATHARINA HOSPITAL   (Netherlands)

^h JEROEN BOSCH HOSPITAL   (Netherlands)

ⁱ AMPHIA HOSPITAL   (Netherlands)

^j MEDISCH SPECTRUM TWENTE   (Netherlands)

^k SLINGELAND HOSPITAL   (Netherlands)

more..

Author keywords

Breast cancer; Combination; Docetaxel; Sequential therapy; Trastuzumab; Treatment beyond progression

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; VOMITING;

EID: 80051766451     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.03.003     Document Type: Article

References (25)

1. Ross JS, Slodkowska EA, Fraser Symmans W, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68.
2. Berns EM, Klijn JG, van Staveren IL, et al. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992;28:697-700.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
5. Baselga J, Carbonell X, Castañeda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71. (Pubitemid 46218708)
6. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firstline treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74. (Pubitemid 46207001)
7. Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 2010;119:127-36.
8. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965-72. (Pubitemid 47312860)
9. Gasparini G, Gion M, Mariani L, et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007;101:355-65. (Pubitemid 46169890)
10. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853-8. (Pubitemid 47477260)
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-6.
13. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:976-83.
14. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
15. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
16. Spanish Breast Cancer Research Group. Benefit of adding trastuzumab to second line chemotherapy in breast cancer patients previously treated with trastuzumab. Available at http://www.clinicaltrials.gov/ct/show/NCT00130507. Accessed March 15, 2011.
17. Montemurro F. Faggiuolo R, Redana S, et al. Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005;23:2866-8; discussion 2868-9. (Pubitemid 46179483)
18. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120-5. (Pubitemid 36939418)
19. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-70. (Pubitemid 41095039)
20. García-Sáenz JA, Martín M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005;6:325-9. (Pubitemid 41715693)
21. Bartsch R, Wenzel C, Hussian D, et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006;6:63.
22. Cancello G, Montagna E, D'Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008;10:R60. Epub 2008 Jul. 16.
23. Montemurro F, Redana S, Nolè F, et al. Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumabcontaining regimens: a retrospective study. BMC Cancer 2008;8:209.
24. Fabi A, Metro G, Ferretti G, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A monoinstitutional experience and systematic review of observational studies. Breast 2008;17:499-505.
25. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37.